An FDA advisory panel determined the meningococcal meningitis vaccine, Menactra, developed by Sanofi-Aventis, is safe and effective, but recommended longer-term studies as a condition of FDA approval. The vaccine is said to last longer than the company's own three- to five-year Menomune limit, and could last longer still with booster shots.

Full Story:

Related Summaries